

# Linear IgA dermatosis induced by captopril

## *Dermatosis IgA lineal*

N. Menezes<sup>1</sup>, P. Varela<sup>1</sup>, A. Furtado<sup>2</sup>, G. Mota<sup>1</sup>, A. Baptista<sup>1</sup>

<sup>1</sup>Serviço de Dermatologia e Venereologia. <sup>2</sup>Serviço de Anatomia Patológica. Centro Hospitalar de Vila Nova de Gaia/Espinho

### Correspondencia:

N. Menezes

Serviço de Dermatologia e Venereologia

Centro Hospitalar de Vila Nova de Gaia/Espinho

Rua Conceição Fernandes

4430 VN Gaia

Tel.: +351936262253

Fax: +351227832755

e-mail: nuno.menezes.dermatologia@gmail.com

### Summary

Linear IgA dermatosis is an auto-immune bullous disease characterized by linear IgA deposition in the basement membrane. Most cases are idiopathic but some are drug-related. These lack mucosal involvement, have spontaneous remission and IgA deposition clearance at the basement membrane after drug cessation.

A 89 year-old patient presenting with symmetric, itchy, tense and translucent bullous lesions located on the upper limbs and abdomen with 2 weeks evolution is reported.

The patient had started captopril regimen two months before.

The diagnosis was histologically confirmed. The patient started prednisolone and changed the hypertension medication from captopril to amlodipine. After 4 weeks an almost complete resolution of the lesions was observed. Prednisolone was slowly tapered and there have been no relapses for almost 2 years.

Skin autoimmune diseases are almost always idiopathic. However some cases can be induced or aggravated by exogenous factors including drugs, trauma, infections, vaccinations, radiographs and UV radiation[1]. Linear IgA bullous dermatosis (LABD), a rare, acquired, autoimmune, heterogeneous subepidermal blistering disorder, is no exception[2]. Patients may present with combinations of annular or grouped papules, vesicles, and bullae. Typically, these lesions are distributed symmetrically on extensor surfaces including elbows, knees, and buttocks[2].

(N. Menezes, P. Varela, A. Furtado, G. Mota, A. Baptista. Linear IgA dermatosis induced by captopril. Med Cutan Iber Lat Am 2008;36(5):252-255)

**Key words:** Linear IgA dermatosis, captopril.

### Resumen

La dermatosis IgA lineal es una enfermedad ampollosa autoinmune caracterizada por la presencia de depósitos IgA lineales en la membrana basal de la epidermis. Muchos casos son idiopáticos sin embargo otros están relacionados con fármacos, no afecta a las mucosas. Así se ha visto que al dejar dichos fármacos se produce una remisión espontánea de los depósitos de la membrana basal.

Hemos tenido ocasión de estudiar un varón de 89 años que presentaba lesiones ampollosas traslúcidas y tensas, pruriginosas, y de distribución simétrica, en extremidades superiores y abdomen. Pocos meses antes había comenzado tratamiento con captopril.

El estudio histológico confirmó el diagnóstico y fue tratado con prednisona sustituyendo el captopril por amlodipina. Cuatro semanas mas tarde se observó una remisión prácticamente completa de sus lesiones. La prednisolona fue retirada de forma paulatina y no ha presentado recidivas después de dos años.

**Palabras clave:** Dermatitis IgA lineal, captopril.




**Figure 1.** Bullous lesions involving the upper limbs and the trunk.

## Case report

A 89 year-old patient presuming by symmetric, itchy, tense and translucent bullous lesions located on the upper limbs and abdomen with 2 weeks evolution is reported. The lesions first started around the umbilicus and distal parts of upper limbs with progressive spreading to the back and thoracic region (Figure 1). An intense burning sensation was described by the patient preceding the appearance of new lesions. The patient was taking captopril for 2 month due to hypertension.

Biopsy specimens were obtained from lesional and perilesional skin for histopathologic examination with hematoxylin-eosin staining and direct immunofluorescence (IF). A subepidermal blister with abundant fibrine and eosinophils in the blister fluid was observed. In the papillary dermis a



**Figure 2.** Subepidermal blistering with abundant fibrine and eosinophils in the blister fluid. A sparse mixed inflammatory infiltrate (neutrophils and eosinophils) was present in the papillary dermis. (Hematoxylin-eosin 4x).

sparse mixed inflammatory infiltrate (neutrophils and eosinophils) was present (Figure 2).

Sections 4 $\mu$ m-thick were prepared and stained with fluorescein isothiocyanate-labeled antibodies to human IgG, IgM, IgA and C3. The direct IF showed continuous linear deposits of IgA at the basement membrane but no evidence of IgG, IgM and C3 (Figure 3).


Therapy with prednisolone (1 mg/kg/day) was started, suspecting of a bullous disease and the hypertension medication was changed from captopril to amlodipine.

After 4 weeks an almost complete resolution of the lesions was observed and prednisolone was slowly tapered for three month period.

After complete resolution and prednisolone withdrawal a new skin biopsy was performed which revealed a normal skin with a negative direct IF. After 2 years of follow-up the patient is without lesions and had no new flares (Figure 4).

## Comment

LABD is a rare subepidermal autoimmune bullous dermatosis almost always idiopathic but several drugs medications were implied as etiologic factors. Vancomycin is the most frequent agent reported[3-5], but other drugs with the potential to induce LABD include diclofenac , furosemide , captopril, lithium, cefamandole, somatostatin[3] phenytoin, trimethoprim-sulfamethoxazole, rifampicin, IL-2, interferon gamma, amiodarone, penicillin G, carbamazepine, piroxicam, atorvastatin and topical iodine[3, 6-19].



**Figure 3.** Direct IF showed continuous linear deposits of IgA at the basement membrane but no evidence of IgG, IgM and C3.



**Figure 4.** The patient without lesions.

Captopril, an angiotensin-II-converting enzyme inhibitor, is a largely used antihypertensive agent that has been associated with a wide variety of cutaneous reactions, including angioedema, urticaria, lichenoid eruptions and pityriasis rosea-like rash. Despite being already established as an etiologic factor to pemphigus, its role as an inducer of other bullous disease has not been frequently reported[20-25]. There are very few case reports from LABD induced by captopril, the last one being from 1996.

Both idiopathic and drug-induced LABD are heterogeneous in clinical presentation[26].

A spectrum of clinical presentations has been described regarding this disease; patients have lesions similar to dermatitis herpetiformis or bullous pemphigoid, but the unique immunofluorescence pattern with linear IgA deposition along the basement membrane allow the diagnosis[3]. Most typically, tense vesicles are arranged in herpetiform, sausage-like, rosette-like or arciform patterns on erythematous or normal-appearing skin. Histology usually reveals subepidermal bullae and an inflammatory infiltrate of the upper dermis, sometimes with microabscesses. Direct IF is a useful tool to allow the differential diagnosis between bullous diseases. Indirect immunofluorescence in

LABD only occasionally reveals circulating IgA anti-basement-membrane-zone antibodies[21].

There are reports of unrelated antibodies in LABD (detected by indirect IF), to a 285 Kd antigen in the lamina densa and sublamina densa regions, a 250 Kd dermal antigen corresponding to collagen VII of anchoring fibrils, BP230 antigen and a 97 kd antigen in the upper lamina lucida which is believed to be an ectodomain of the BP230 antigen produced by proteolysis[3, 27-29], but direct IF remains the gold standard for diagnosis.

However, drug-induced LABD, according to Kuechle et al. appears to differ from idiopathic cases in some aspects, namely lack of mucosal involvement, spontaneous remission after drug cessation and IgA deposition clearance at the basement membrane once the cutaneous lesions resolve[3]. However these clues for a drug-induced IgA bullous dermatosis can't be viewed in a dogmatic way, because in a literature review conducted by Palmer, 13 of 29 patients with LABD drug-induced had mucosal involvement[27].

Our case lacked mucosal involvement and had a significant improvement of the lesions after suspicious drug withdrawal. We also performed a skin biopsy after dermatosis resolution which was normal, with a negative direct IF to all antibodies tested. This together with the time relationship between start of captopril intake and the appearance of the lesions, despite the absence of a drug rechallenge, make us believe this is a case of drug induced LABD.

In drug-induced cases the withdrawal of the offending agent normally induces rapid resolution of the dermatosis. However some authors treat actively the disease with the objective of a more rapid remission[3, 28]. In our case due to the pemphigoid-like presentation corticosteroids were started and slowly tapered. After that there were no flairs, being without lesions for three years now.

## References

1. Salmhofer W, Soyer P, Wolf P, Födinger D, Hödl S, Kerl H. UV light-induced linear IgA dermatosis. *J Am Acad Dermatol* 2004;50:109-15.
2. Camilleri M, Pace JL. Linear IgA bullous dermatosis induced by piroxicam. *J Eur Acad Dermatol Venereol* 1998;10:70-2.
3. Kuechle MK, Stegemeir E, Maynard B, Gibson LE, Kristin ML, Peters MS: Drug-induced IgA bullous dermatosis: Report of six cases and review of the literature. *J Am Acad Dermatol* 1994;30:187-92.
4. Danielsen AG, Thomsen K. Vancomycin-induced linear IgA bullous disease. *Br J Dermatol* 1999;141:756-7.
5. Baden LA, Apovian C, Imber MJ, Dover JS. Vancomycin-induced linear IgA bullous dermatosis. *Arch Dermatol* 1988;124:1186-8.
6. Gabrielsen TO, Staerfeldt F, Thrune PO. Drug-induced bullous dermatosis with linear IgA deposits along the basement membrane. *Acta Derm Venereol* 1981;61:439-41.
7. Cerottini JP, Ricci C, Guggisberg D, Panizzon Rg. Drug-induced linear IgA bullous dermatosis probably induced by furosemid. *J Am Acad Dermatol* 1999;41:103-5.
8. Klein L, Shmunes E, Carter J. Linear IgA bullous dermatosis related to captopril treatment. *Cutis* 1989;41:103-5.
9. McWhirter JD, Hashimoto K, Fayne S, Ito K. Linear IgA bullous dermatosis related to lithium carbonate. *Arch Dermatol* 1987;123:1120-2.
10. Argenyi Z, Bergfeld W, Valenzuela R, McMahon J, Taylor J. Adult linear IgA disease associated with an erythema multiforme-like drug reaction. *Cleve Clin J Med* 1987;54:445-50.
11. Acostamadiedo JM, Perniciaro C, Rogers RS III. Phenytoin-induced linear IgA bullous disease. *J Am Acad Dermatol* 1998;38:352-6.
12. Travan A, Pezen DS, Medenica M, Michelson GC, Vogelzang N, Soltani KM. Interleu-

- kin-2 associated linear IgA bullous dermatosis. *J Am Acad Dermatol* 1996;35:865-7.
13. Guillaume JC, Escudier B, Espagne E, Roujeau JC, Prost C, Domart P. Dermatoase bulleuse avec dépôts linéaire d'IgA le long de la membrane basale au cours d'un traitement par interferon gamma et interleukin 2. *Ann Dermatol Venerol* 1990;117:899-902.
14. Primka EJ, Liranzo MO, Bergfeld WF, Dijkstra JW. Amiodarone-induced linear IgA disease. *J Am Acad Dermatol* 1994;32:809-11.
15. Combermale P, Gavaud C, Cozzani E, Nicolas JF, Guennoc B, Dusseau JY. Dermatoase à IgA linéaire induite par la penicilline G. *Ann Dermatol Venerol* 1993;120:847-8.
16. Cohen LM, Ugent RB. Linear IgA bullous dermatosis occurring after carbamazepine. *J Am Acad Dermatol* 2002;46:S32-3.
17. Plunkett RW, Chiarello SE, Beutner EH. Linear IgA bullous dermatitis in one of two piroxicam-induced eruptions: a distinct direct immunofluorescence trend revealed by the literature. *J Am Acad Dermatol* 2001;44:689-92.
18. König C, Eickert A, Scharfetter-Kochanek K, Krieg T, Hunzelmann N. Linear IgA bullous dermatosis induced by atorvastatin. *J Am Acad Dermatol* 2001;44:689-92.
19. Wakelin SH, Wojnarowka F. Linear IgA disease exacerbated by topical iodine preparations. *Br J Dermatol* 1994;31:809-11.
20. Friedman IS, Rudikoff D, Phelps RG, Sapidin AN. Captopril-triggered linear IgA bullous dermatosis. *International Journal of Dermatology* 1998;37:608-12.
21. Wood SM, Mann RD, Rawlins MD. Angioedema and urticaria associated with angiotensin converting enzyme inhibitors. *Br Med J* 1987;294:91-2.
22. Phillips WG, Vaughan-Jones S, Jenkins R, Brathnach SM. Captopril-induced lichenoid eruption. *Clin Exp Dermatol* 1994;19:317-20.
23. Wilken JK, Kirkendall WM. Pityriasis rosea-like rash from captopril. *Arch Dermatol* 1982;118:186-87.
24. Kaplan RP, Potter TS, Fox JN. Drug-induced pemphigus related to angiotensin-converting enzyme inhibitors. *J Am Acad Dermatol* 1992;26:364-66.
25. Sala F, Crosti C, Monti M, DeBitonto A. Cutaneous pathology due to captopril – observations on 2 clinical cases. *G Ital Dermatol Venerol* 1983;118:89-93.
26. Janniger CK, Wiltz H, Scharitz RA, et al. Linear IgA bullous dermatosis: a polymorphic disorder. *Cutis* 1990;45:37-42.
27. Palmer RA, Ogg G, Allen J, Banerjee A, Ryatt KS, Ratnavel R, Wojnarowska. Vancomycin-induced linear IgA disease with autoantibodies to BP 180 and LAD 285. *Br J Dermatol* 2001;145:816-20.
28. Wojnarowska F, Whitehead P, Leigh IM. Identification of the target antigen in chronic bullous disease of childhood and linear IgA disease of adults. *Br J Dermatol* 1991;124:157-62.
29. Zane JJ, Taylor TB, Kadunce DP. Identification of the cutaneous basement membrane zone antigen and isolation of antibody in linear immunoglobulin A bullous dermatosis. *J Clin Invest* 1990;85:812-20.